Back A A A Font Size Receive E-mail Alerts Press Releases

Talos™ Thoracic Stent Graft System Gains CFDA Green-Path


Shanghai, China – On September 27, Talos™ Thoracic Stent Graft System ("Talos™"), self-developed by MicroPort Endovascular (Shanghai) Co., Ltd. ("MicroPort® Endovascular"), was approved to enter the special Green-Path by China Food and Drug Administration ("CFDA"), which is rapid-track of review and approval procedure for innovative medical devices. The Green-Path will significantly expedite the approval time and meanwhile it demonstrated the recognition of Chinese government authorities in Talos™.
The traditional treatment of aortic dissection is to replace aorta in lesion segment by open surgery, which has high mortality rate and high incidence rate of complications due to large trauma. Thoracic endovascular aneurysm repair ("TEVAR") features small incision, short operative time, and fast postoperative recovery, resulting in easier operation and lower mortality rate. Thus, TEVAR has gradually taken place of the traditional open surgery to become the preferred choice of treating Type B aortic dissection. But subject to the current technology, differences in pathophysiology of the disease and individual anatomical, the treatment using stent graft also has its own limitations: The lesion segment of aortic dissection is usually very long involving descending aorta and even abdominal aorta, however the existing thoracic stent grafts are often not long enough to completely cover the lesions, failing to open the distal true lumen and keep the blood of whole aorta vascular flowing smoothly after primary tear occlusion. But, if using long stent graft in the TEVAR, it will affect the blood supply of thoracic spinal cord and lumbar spinal cord, increasing the risk of spinal cord ischemia after the surgery. MicroPort® Endovascular's Talos™ extents the covered length of the SG (Maximum 260mm) to open the distal true lumen and ensure the patency of the aorta, and at the same time innovatively adopts micropores design at the distal end of the SG to ensure the distal branch vessels (e.g., intercostal arteries) patency so as to reduce the incidence of spinal cord ischemia.
CFDA Green-Path on China's Innovative Medical Devices is critically important approach introduced by the government authority to encourage the innovations of medical devices and promote the application of new technologies in the healthcare industry. Innovative medical devices entering Green-Path procedure will receive preferential review process by Food and Drug Administrations to assign special personnel to process the submissions, which will significantly accelerate the approval process and product launch in market. Other than Talos™, three products of MicroPort® Endovascular also entered the CFDA Green-Path, including Castor® Branched Aortic Stent Graft System ("Castor®"), Reewarm® PTX Drug Coated Balloon Dilation Catheter and Minos™ Ultra Low-Profile AAA Stent-Graft System. Among them, Castor® gained CFDA approval in June, 2017.

About MicroPort®

MicroPort Scientific Corporation (the "Group") is a leading medical device company with business focusing on innovating, manufacturing, and marketing high-quality and high-end medical devices globally. With a diverse portfolio of products now being used at an average rate of one for every 12 seconds in thousands of major hospitals around the world, the Group maintains world-wide operations in a broad range of business segments including Cardiovascular, Orthopedic, Cardiac Rhythm Management, Electrophysiological, Endovascular, Neurovascular, Surgical, Diabetes Care and Endocrinal Management, and others. MicroPort® is dedicated to becoming a patient oriented global enterprise improve and reshape patient lives through application of innovative science and technology.

For more information, please refer to:

Forward-Looking Statements

Some information contained on this website contains forward-looking statements. These forward-looking statements include, without limitation, those regarding our future financial position, our strategy, plans, objectives, goals and targets, future developments in the markets where we participate or are seeking to participate, and any statements preceded by, followed by or that include the words "believe", "intend", "expect", anticipate", "project", "estimate", "predict", "is confident", "has confidence" and similar expressions are also intended to identify forward-looking statements. Such statements are based upon the current beliefs and expectations of MicroPort®'s management and are subject to significant risks and uncertainties. MicroPort Scientific Corporation undertakes no obligation to update any of the statements. These forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties and other factors that could cause actual future results to differ materially from current expectations include, but are not limited to, general industry and economic conditions, PRC governmental policies and regulations relating to the medical device manufacturing industry, competition in the medical device manufacturing industry, our ability to develop new products and stay abreast of market trends and technological advances, our goals and strategies, our ability to execute strategic acquisitions of, investments in or alliances with other companies and businesses, fluctuations in general economic and business conditions in China.

This document is for information purposes only and does not constitute or form part of any offer or invitation to sell or the solicitation of an offer or invitation to purchase or subscribe for any securities of MicroPort Scientific Corporation, and no part of it shall form the basis of, or be relied upon in connection with, any agreement, arrangement, contract, commitment or investment decision in relation thereto whatsoever.

All rights reserved.
Copyright © 1998-2018 MicroPort Scientific Corporation

Leanne Li
Board Secretary and Vice President of Corporate General Affairs
MicroPort Scientific Corporation
Tel: (86)(21) 38954600-6953


[Prev]:MicroPort® Enters into Binding Letter of Intent to Buy Cardiac Rhythm Management Business Franchise from LivaNova for $190 Million
[Next]:MicroPort® Hosts Training Course of Medical Device Inspector Training Base